IN.ECTIOUS DISEASES AND VACCINES
Tat co-localizes in endocytic vesicles with the B-subunit of cholera toxin and with endogenous or transfected caveolin, but not with transferrin or the early endosome marker EEA1. The Tat-containing vesicles were visualized at high resolution in living cells. They were found to contain ∼300 molecules of GPF-Tat per vesicle and to display a slow, linear movement towards the nucleus with an average velocity of 3 microm/h. Finally, Tat internalization and nuclear translocation were also studied after cell treatment with different drugs. Notably, internalization was unaffected by nocodazole and taxol -which affect microtubule trafficking -, but strongly reduced by cytochalasin D -which disrupts cell microfilaments -. In addition, Tat internalization was blocked by cell treatment with agents that disrupt cell membrane lipid rafts, such as treatment with methylbeta-cyclodextrin, whereas Tat containing endosomes are resistant to Triton X-100 solubilization. In addition, over-expression of an Eps-15 dominant negative mutant impaired transferrin uptake but did not affect Tat internalization.
Taken together, these results indicate that internalization of extracellular HIV Tat fusion proteins requires binding of the protein to cell surface proteoglycans containing heparin sulfate and occurs through caveolar endocytosis that emanates from cell membrane lipid rafts.
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Negative Small interfering RNAs (siRNAs) can induce potent gene silencing by directing degradation of cognate mRNA. Controlled expression of siRNA would be highly attractive especially since reports indicate that even short double stranded RNA molecules can induce a nonspecific interferon response. We have designed an HIV inducible short hairpin siRNA system in which part of the Drosophila hsp70 promoter (TATA box and surrounding sequences) is cloned downstream of the HIV-1 LTR and TAR region. We demonstrate shRNA expression only in presence of HIV-1 Tat. Cells infected with HIV-1 proviral DNA can efficiently induce shRNA expression from this construct, which in turn inhibits viral replication, thus establishing a negative feedback loop. These results demonstrate for the first time a functional HIV-1 inducible siRNA system. The replication-defective lentiviral vectors are able to transduce a wide array of quiescent cell types with sustained long-term expression of the genes within the vector backbone. These properties make them favorable vectors for anti-HIV-1 therapeutic gene delivery. The recently discovered small interfering RNA(siRNA) mediated RNA interference provides a powerful new tool for gene silencing in a sequence specific manner, which suggest the potential of siRNAs for gene therapy application. A stable expression system of siRNAs and the efficient delivery vehicle of lentiviral vectors would prove an excellent match as a powerful gene therapy tool. We have developed lentiviral vectors expressing U6 pol III promoter-driven short hairpin RNAs (shRNAs) targeting the rev and tat mRNAs of HIV-1. Utilizing these shRNAs we have achieved potent inhibition of HIV-1 replication in primary cells. Up to date, the majority of HIV-1 gene therapy protocols target a single therapeutic gene. Like any therapeutic approach for inhibition of HIV infection, gene therapy is also faced with the problem of development of viral variants that are resistant to therapeutic agents. We hypothesize that if a combination of therapeutic genes targeting different viral products and steps in the viral life cycle is used, the probability of viral escape mutants will be greatly reduced. Furthermore, there is the possibility of synergy between the different gene therapy agents. Previously, we created the pol III expressing cassettes expressing an anti-CCR5 ribozyme or a nucleolar localizing TAR decoy and cloned them into a self-inactivating lentiviral vector. Each of the constructs showed marked anti-HIV-1 activities. In this study, we combined the shRNAs with the ribozyme or the RNA decoy, or all three constructs into a single vector backbone. Each of these therapeutic RNAs targets a different gene and blocks HIV infection by a distinct mechanism. After transduction with the vectors and infection with HIV-1, a potential synergistic effect was apparent in CD34 + hematopoietic stem cells and primary T cells. We have also developed the vectors expressing only the various therapeutic genes but excluding the reporter gene and WPRE sequence to eliminate any elements that potentially interfere with the expression of the therapeutic genes or have adverse effects on target cells. Our longterm goal is to develop vectors suitable for human gene therapy. The human severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly infectious agent that requires specific biosafety level 3 laboratory practices. The present study investigated the possibility to pseudotype an HIV-based vector with the SARSCoV spike envelope protein for facilitating the characterization of this envelope in a safer and less restrictive environment. Spikepseudotyped HIV vector (spike-HIV) could be produced and concentrated to generate vector stocks containing in the range of 10 5 transducing units (TU) per ml as determined by limiting dilution on 293T and VeroE6 cells. Spike-HIV vector was compared to wildtype SARS-CoV for transduction/infection of different tissues and the ability to detect neutralizing antibody (NAB) to SARS-CoV from immune serum. Results show that Spike-HIV vector encoding for LacZ (Spike-HIV-LacZ) was slightly more sensitive at detecting the presence of NAB from SARS-CoV immune sera than wild-type SARS-CoV. In addition, both Spike-HIV-LacZ and SARS-CoV could transduce/infect culture of primary human cells such as dendritic and airway epithelial cells. Localization of Spike-HIV-LacZ and SARS-CoV following in vivo administration in the airway of mice will be presented. Overall, results indicate that it is possible to pseudotype HIV vector with the SARS-CoV spike glycoprotein for studying B cell response directed against the virus as well as its natural viral tropism. Spike-HIV vector should facilitate the characterization of SARS-CoV tropism to a high number of different cell types in vitro and in vivo. This could help selecting an optimal animal model and provide a better understanding of the pathogenesis associated with SARS-CoV infection.
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